Advertisement

Tumor Biology

, Volume 35, Issue 7, pp 6933–6939 | Cite as

Expression and biological role of cytoglobin in human ovarian cancer

  • Haiying Chen
  • Xia Zhao
  • Tao MengEmail author
Research Article

Abstract

Loss of cytoglobin is found to be involved in the progression of several human cancers. However, its expression pattern and biological roles in human ovarian cancers are not clear. In this study, we examined cytoglobin expression in 118 archived ovarian cancer specimens using immunohistochemistry. A total of 72 specimens (61.0 %) showed cytoglobin downregulation. cytoglobin downregulation positively correlated with advanced FIGO stage and tumor grade. Cytoglobin plasmid transfection was performed in SKOV3 cell line and siRNA knockdown was carried out in SW626 cell line. MTT, colony formation assay and matrigel invasion assay were carried out to assess the role of cytoglobin on cell proliferation and invasion. Cytoglobin overexpression inhibited cell growth, invasion, cell cycle progression and cyclin D1 expression in SKOV3 cell line and its depletion promoted cell proliferation, invasion, cell cycle transition and cyclin D1 expression. In conclusion, cytoglobin is downregulated in ovarian cancers and associated with advanced stage. Our data provides evidence that cytoglobin regulates the ovarian cancer cell proliferation and invasion.

Keywords

Cytoglobin Ovarian cancer Proliferation Invasion 

Notes

Conflicts of interest

None.

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413–37.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang YF, Lang HY, Yuan J, Wang J, Wang R, Zhang XH, et al. Overexpression of keratin 17 is associated with poor prognosis in epithelial ovarian cancer. Tumour Biol. 2013;34(3):1685–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Darcy KM, Birrer MJ. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol. 2010;117(3):429–39.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Despierre E, Lambrechts D, Neven P, Amant F, Lambrechts S, Vergote I. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol. 2010;117(2):358–65.CrossRefPubMedGoogle Scholar
  6. 6.
    Fang Y, Li Z, Wang X, Zhang S. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumour Biol. 2012;33(6):2299–306.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhao Y, Chen S, Gou WF, Xiao LJ, Takano Y, Zheng HC. Aberrant Beclin 1 expression is closely linked to carcinogenesis, differentiation, progression, and prognosis of ovarian epithelial carcinoma. Tumour Biol. 2014;35(3):1955–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Burmester T, Ebner B, Weich B, Hankeln T. Cytoglobin: a novel globin type ubiquitously expressed in vertebrate tissues. Mol Biol Evol. 2002;19(4):416–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Weber RE, Fago A. Functional adaptation and its molecular basis in vertebrate hemoglobins, neuroglobins and cytoglobins. Respir Physiol Neurobiol. 2004;144(2–3):141–59.CrossRefPubMedGoogle Scholar
  10. 10.
    Presneau N, Dewar K, Forgetta V, Provencher D, Mes-Masson AM, Tonin PN. Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1–q25.2. Mol Carcinog. 2005;43(3):141–54.CrossRefPubMedGoogle Scholar
  11. 11.
    Xinarianos G, McRonald FE, Risk JM, Bowers NL, Nikolaidis G, Field JK, et al. Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer. Hum Mol Genet. 2006;15(13):2038–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Wojnarowicz PM, Provencher DM, Mes-Masson AM, Tonin PN. Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. Int J Oncol. 2012;40(6):1865–80.PubMedGoogle Scholar
  13. 13.
    Shivapurkar N, Stastny V, Okumura N, Girard L, Xie Y, Prinsen C, et al. Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Cancer Res. 2008;68(18):7448–56.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Shaw RJ, Omar MM, Rokadiya S, Kogera FA, Lowe D, Hall GL, et al. Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer. Br J Cancer. 2009;101(1):139–44.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Xu HW. Huang YJ, Xie ZY, Lin L, Guo YC, Zhuang ZR, Lin XP, Zhou W, Li M, Huang HH, Wei XL, Man K, and Zhang GJ, The expression of cytoglobin as a prognostic factor in gliomas: a retrospective analysis of 88 patients. BMC Cancer. 2013;13:247.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Fang J, Ma I, Allalunis-Turner J. Knockdown of cytoglobin expression sensitizes human glioma cells to radiation and oxidative stress. Radiat Res. 2011;176(2):198–207.CrossRefPubMedGoogle Scholar
  17. 17.
    Wojnarowicz PM, Provencher DM, Mes-Masson AM, and Tonin PN, Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer. Int J Oncol. 2012;40(6):1865–80.Google Scholar
  18. 18.
    Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11(18):6422–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Guo J, Xia B. Meng F, and Lou G, miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor. Tumour Biol. 2014;35(2):1557–64.CrossRefPubMedGoogle Scholar
  20. 20.
    Singer G, Oldt 3rd R, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25(11):1620–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol. 2003;21(11):2085–93.CrossRefPubMedGoogle Scholar
  23. 23.
    Ishikawa T, Furihata M, Ohtsuki Y, Murakami H, Inoue A, Ogoshi S. Cyclin D1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcinoma. Br J Cancer. 1998;77(1):92–7.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Shirali S, Aghaei M, Shabani M, Fathi M, Sohrabi M, Moeinifard M. Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3. Tumour Biol. 2013;34(2):1085–95.CrossRefPubMedGoogle Scholar
  25. 25.
    Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res. 2004;10(15):5168–77.CrossRefPubMedGoogle Scholar
  26. 26.
    Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009;69(16):6565–72.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Gynaecology and ObstetricsFirst Affiliated Hospital of China Medical UniversityShenyangChina

Personalised recommendations